Tirofiban After Tenecteplase in Stroke

Adjunctive tirofiban was linked to higher rates of positive 90-day outcomes in acute ischemic stroke.

1

The INSTANT trial found that tirofiban improved functional outcomes at 90 days in stroke patients with inadequate response to tenecteplase.
2

In the trial, 64% of patients receiving tirofiban achieved an excellent outcome, compared to 52% receiving placebo.
3

The trial included 359 patients with acute ischemic stroke and excluded those with large-vessel occlusion or cardioembolic sources.
4

Tirofiban was administered after tenecteplase, with a number needed to treat of 8.7 for achieving excellent outcomes.
5

The study's findings may not apply to patients with minor strokes or those treated outside the early thrombolysis window.

1